Bios Life emerges from stealth with $25M to build digital twins for cancer screening
Tech Funding News Sofia Chesnokova
Bios Life just raised $25M to build cancer-risk “digital twins.” It’s betting doctors can move from one-off scans to constant monitoring.
Based on reporting by Tech Funding News, Sofia Chesnokova — read the original for the full story.
Summary, retelling and take written by AI under human oversight; images are AI-generated illustrations. How we work · Report an error
Bios Life has come out of stealth with $25 million in seed funding and a plan that sounds futuristic because, honestly, it is. The Boston healthtech wants to build ongoing cancer risk models — “digital twins” — that update as new clinical, lab, and genetic data comes in. Redmile, Vsquared Ventures, and Kindred Capital led the round, and the company says this is its first outside funding.
The pitch is aimed at a very real problem. Kevin Oeffinger of Duke Cancer Institute says cancer screening has barely changed in two or three decades, and many people at elevated risk still miss standard screening altogether. Bios Life is targeting two groups that overlap a lot: cancer survivors and people with higher genetic risk. Together, the company says, that’s more than 40 million Americans.
The team is built around BioNTech veterans. Ryan Richardson, the CEO, was BioNTech’s chief strategy officer and sat on InstaDeep’s board after BioNTech bought the company in 2023. Zach Taylor, once a senior vice president at BioNTech, is chief operating and business officer. The company also brought in a breast radiologist, a product lead from One Medical and Galileo, and the former head of InstaDeep’s genomics AI research.
Bios Life’s model is not just about flagging risk; it wants to wrap risk modelling and care delivery into one system. The company says patients will be seen through a virtual clinic with licensed teams working alongside cancer centres, and it plans to integrate hereditary genetic testing through Ambry Genetics, a Tempus company. Its US platform is set to launch in the second half of 2026, with a waitlist already open.
The data side matters too. Bios Life has a multi-year partnership with Tempus, which it will use to train and test its models on anonymous oncology data. It also owns commercial rights to Nucleotide Transformer, a genomics foundation model created by BioNTech-InstaDeep. Bios Life says the model can read genomic signals down to a single nucleotide. That’s a powerful claim in a crowded field, but the real test is simpler: whether patients stick with continuous monitoring when medicine has spent decades teaching them to show up once in a while and hope for the best.
My take — AI-written commentary, not fact-checked reporting
This is the kind of healthcare AI pitch that actually deserves scrutiny, because the problem is not model quality, it’s whether patients and clinicians will use it between appointments. The industry keeps mistaking more data for better care, which is very on-brand for tech and very annoying for everyone else. If Bios Life can make continuous follow-up feel normal instead of burdensome, that would be a real shift; if not, it’s just another shiny dashboard with oncology branding.
Read more about this at: Tech Funding News
Related stories
Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform
Tech.eu · 1 month ago ·
4